{"url":"https://lda.gov/api/v1/filings/3b416d20-48aa-4ead-8648-66c1a5de2a6b/","filing_uuid":"3b416d20-48aa-4ead-8648-66c1a5de2a6b","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/3b416d20-48aa-4ead-8648-66c1a5de2a6b/print/","filing_document_content_type":"text/html","income":null,"expenses":"1410000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Andrew Kaplan","dt_posted":"2026-04-20T11:03:24-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"670 Maine Ave SW","registrant_address_2":"Suite 210","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20024","registrant":{"id":57954,"url":"https://lda.gov/api/v1/registrants/57954/","house_registrant_id":35264,"name":"TAKEDA PHARMACEUTICALS AMERICA, INC.","description":"Pharmaceutical Company","address_1":"670 Maine Ave SW","address_2":"Suite 210","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20024","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ANDREW KAPLAN","contact_telephone":"+1 202-649-4004","dt_updated":"2026-07-29T15:10:28.128353-04:00"},"client":{"id":160416,"url":"https://lda.gov/api/v1/clients/160416/","client_id":12,"name":"TAKEDA PHARMACEUTICALS AMERICA INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2009-11-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"FY 2025 Budget Resolution - Pharmaceutical Related Provisions","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152608,"prefix":null,"prefix_display":null,"first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"LISOWSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145038,"prefix":null,"prefix_display":null,"first_name":"KIRSTEN","nickname":null,"middle_name":null,"last_name":"POWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":64771,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"KAPLAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Review of proposed rule regarding testing of Medicare part B prescription drug models Medicare payment proposals Medicare telehealth proposals CMS Transparency in Coverage Final Rule (CMS-9915-F) Request for Regulatory Clarification with Medicare Part B Group (CMS) Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 Request for Regulatory Clarification with Medicare Administrative Contractor (CMS) Discussions on biosimilars related to IRA Discussions on spillover related to the IRA Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Discussions on reforming the Inflation Reduction Act Discussions on orphan drugs related to the IRA Discussions on treatment of small molecule drugs related to IRA H.R.1 492, S. 832, EPIC Act of 2025 HR 4229 Protecting Patient Access to Cancer & Complex Therapies Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64771,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"KAPLAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145038,"prefix":null,"prefix_display":null,"first_name":"KIRSTEN","nickname":null,"middle_name":null,"last_name":"POWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146979,"prefix":null,"prefix_display":null,"first_name":"REBECCA","nickname":null,"middle_name":null,"last_name":"MANDELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57722,"prefix":null,"prefix_display":null,"first_name":"SHELLEY","nickname":null,"middle_name":null,"last_name":"STEWART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152608,"prefix":null,"prefix_display":null,"first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"LISOWSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Clarify or reform the 340B program Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) Drug pricing, including House and Senate draft bills Bayh-Dole march-in rights policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64771,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"KAPLAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145038,"prefix":null,"prefix_display":null,"first_name":"KIRSTEN","nickname":null,"middle_name":null,"last_name":"POWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57722,"prefix":null,"prefix_display":null,"first_name":"SHELLEY","nickname":null,"middle_name":null,"last_name":"STEWART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152608,"prefix":null,"prefix_display":null,"first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"LISOWSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Administration's Global Tax Proposal General issues around 2026 Reconciliation/Inbound Concerns","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":57722,"prefix":null,"prefix_display":null,"first_name":"SHELLEY","nickname":null,"middle_name":null,"last_name":"STEWART","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"General intellectual property policy issues Issues related to proposed Tariffs - all pharmaceutical related provisions","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152608,"prefix":null,"prefix_display":null,"first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"LISOWSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57722,"prefix":null,"prefix_display":null,"first_name":"SHELLEY","nickname":null,"middle_name":null,"last_name":"STEWART","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145038,"prefix":null,"prefix_display":null,"first_name":"KIRSTEN","nickname":null,"middle_name":null,"last_name":"POWELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"Discussions around Supply Chain implications","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152608,"prefix":null,"prefix_display":null,"first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"LISOWSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57722,"prefix":null,"prefix_display":null,"first_name":"SHELLEY","nickname":null,"middle_name":null,"last_name":"STEWART","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}